|
1
|
Llosa NJ, Cruise M, Tam A, Wicks EC,
Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS,
et al: The vigorous immune microenvironment of microsatellite
instable colon cancer is balanced by multiple counter-inhibitory
checkpoints. Cancer Discov. 5:43–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ganesh K, Stadler ZK, Cercek A, Mendelsohn
RB, Shia J, Segal NH and Diaz LA Jr: Immunotherapy in colorectal
cancer: Rationale, challenges and potential. Nat Rev Gastroenterol
Hepatol. 16:361–375. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Picard E, Verschoor CP, Ma GW and Pawelec
G: Relationships between immune landscapes, genetic subtypes and
responses to immunotherapy in colorectal cancer. Front Immunol.
11:3692020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density, and location of immune
cells within human colorectal tumors predict clinical outcome.
Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Galon J, Fridman WH and Pagès F: The
adaptive immunologic microenvironment in colorectal cancer: A novel
perspective. Cancer Res. 67:1883–1886. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marabelle A, Fakih M, Lopez J, Shah M,
Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin
JA, Miller WH Jr, et al: Association of tumour mutational burden
with outcomes in patients with advanced solid tumours treated with
pembrolizumab: Prospective biomarker analysis of the multicohort,
open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21:1353–1365.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galon J, Mlecnik B, Bindea G, Angell HK,
Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et
al: Towards the introduction of the ‘Immunoscore’ in the
classification of malignant tumours. J Pathol. 232:199–209. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schumacher TN and Schreiber RD:
Neoantigens in cancer immunotherapy. Sciencec. 348:69–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Galon J and Bruni D: Tumor immunology and
tumor evolution: Intertwined histories. Immunity. 52:55–81. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weiser MR: AJCC 8th edition: Colorectal
cancer. Ann Surg Oncol. 25:1454–1455. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yomoda T, Sudo T, Kawahara A, Shigaki T,
Shimomura S, Tajiri K, Nagasu S, Fujita F, Kinugasa T and Akagi Y:
The immunoscore is a superior prognostic tool in stages II and III
colorectal cancer and is significantly correlated with programmed
death-ligand 1 (PD-L1) expression on tumor-infiltrating mononuclear
cells. Ann Surg Oncol. 26:415–424. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schneider CA, Rasband WS and Eliceiri KW:
NIH image to ImageJ: 25 years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fujiyoshi K, Bruford EA, Mroz P, Sims CL,
O'Leary TJ, Lo AWI, Chen N, Patel NR, Patel KP, Seliger B, et al:
Opinion: Standardizing gene product nomenclature-a call to action.
Proc Natl Acad Sci USA. 118:e20252071182021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kirilovsky A, Marliot F, El Sissy C,
Haicheur N, Galon J and Pagès F: Rational bases for the use of the
immunoscore in routine clinical settings as a prognostic and
predictive biomarker in cancer patients. Int Immunol. 28:373–382.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chaudhary R, Quagliata L, Martin JP,
Alborelli I, Cyanam D, Mittal V, Tom W, Au-Young J, Sadis S and
Hyland F: A scalable solution for tumor mutational burden from
formalin-fixed, paraffin-embedded samples using the oncomine tumor
mutation load assay. Transl Lung Cancer Res. 7:616–630. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Overman MJ, Lonardi S, Wong KYM, Lenz HJ,
Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill
A, et al: Durable clinical benefit with nivolumab plus ipilimumab
in DNA mismatch repair-deficient/microsatellite instability-high
metastatic colorectal cancer. J Clin Oncol. 36:773–779. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Noepel-Duennebacke S, Juette H, Schulmann
K, Graeven U, Porschen R, Stoehlmacher J, Hegewisch-Becker S, Raulf
A, Arnold D, Reinacher-Schick A and Tannapfel A: Microsatellite
instability (MSI-H) is associated with a high immunoscore but not
with PD-L1 expression or increased survival in patients (pts.) with
metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox)
and fluoropyrimidine (FP) with and without bevacizumab (bev): A
pooled analysis of the AIO KRK 0207 and RO91 trials. J Cancer Res
Clin Oncol. 147:3063–3072. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
de Jong AE, van Puijenbroek M, Hendriks Y,
Tops C, Wijnen J, Ausems MG, Meijers-Heijboer H, Wagner A, van Os
TA, Bröcker-Vriends AH, et al: Microsatellite instability,
immunohistochemistry, and additional PMS2 staining in suspected
hereditary nonpolyposis colorectal cancer. Clin Cancer Res.
10:972–980. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Truninger K, Menigatti M, Luz J, Russell
A, Haider R, Gebbers JO, Bannwart F, Yurtsever H, Neuweiler J,
Riehle HM, et al: Immunohistochemical analysis reveals high
frequency of PMS2 defects in colorectal cancer. Gastroenterology.
128:1160–1171. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Senter L, Clendenning M, Sotamaa K, Hampel
H, Green J, Potter JD, Lindblom A, Lagerstedt K, Thibodeau SN,
Lindor NM, et al: The clinical phenotype of Lynch syndrome due to
germ-line PMS2 mutations. Gastroenterology. 135:419–428. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ten Broeke SW, van der Klift HM, Tops CMJ,
Aretz S, Bernstein I, Buchanan DD, de la Chapelle A, Capella G,
Clendenning M, Engel C, et al: Cancer risks for PMS2-associated
Lynch syndrome. J Clin Oncol. 36:2961–2968. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chan TA, Yarchoan M, Jaffee E, Swanton C,
Quezada SA, Stenzinger A and Peters S: Development of tumor
mutation burden as an immunotherapy biomarker: Utility for the
oncology clinic. Ann Oncol. 30:44–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hwang HS, Kim D and Choi J: Distinct
mutational profile and immune microenvironment in
microsatellite-unstable and POLE-mutated tumors. J Immunother
Cancer. 9:e0027972021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Salem ME, Bodor JN, Puccini A, Xiu J,
Goldberg RM, Grothey A, Korn WM, Shields AF, Worrilow WM, Kim ES,
et al: Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific
alterations and tumor mutational burden in 1057 microsatellite
instability-high solid tumors. Int J Cancer. 147:2948–2956. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boland CR and Goel A: Microsatellite
instability in colorectal cancer. Gastroenterology.
138:2073–2087.e3. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Angelova M, Charoentong P, Hackl H,
Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik
B, Galon J and Trajanoski Z: Characterization of the
immunophenotypes and antigenomes of colorectal cancers reveals
distinct tumor escape mechanisms and novel targets for
immunotherapy. Genome Biol. 16:642015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Giannakis M, Mu XJ, Shukla SA, Qian ZR,
Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, et
al: Genomic correlates of immune-cell infiltrates in colorectal
carcinoma. Cell Rep. 15:857–865. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pagès F, Mlecnik B, Marliot F, Bindea G,
Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al:
International validation of the consensus Immunoscore for the
classification of colon cancer: A prognostic and accuracy study.
Lancet. 391:2128–2139. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mlecnik B, Bindea G, Angell HK, Maby P,
Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M,
Fredriksen T, et al: Integrative analyses of colorectal cancer show
immunoscore is a stronger predictor of patient survival than
microsatellite instability. Immunity. 44:698–711. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chalabi M, Fanchi LF, Dijkstra KK, Van den
Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C,
Beets GL, Snaebjornsson P, et al: Neoadjuvant immunotherapy leads
to pathological responses in MMR-proficient and MMR-deficient
early-stage colon cancers. Nat Med. 26:566–576. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chakrabarti S, Huebner LJ, Finnes HD,
Muranyi A, Singh S, Clements J, McWilliams RR, Hubbard JM,
Shanmugam K and Sinicrope FA: Intratumoral CD3+ and
CD8+ T-cell densities in patients with deficient DNA
mismatch repair (dMMR) metastatic colorectal cancer (mCRC)
receiving programmed death-1 (PD-1) blockade. J Clin Oncol. 37 (15
Suppl):S35322019. View Article : Google Scholar
|
|
35
|
Chatterjee N and Walker GC: Mechanisms of
DNA damage, repair, and mutagenesis. Environ Mol Mutagen.
58:235–263. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nicolas E, Golemis EA and Arora S: POLD1:
Central mediator of DNA replication and repair, and implication in
cancer and other pathologies. Gene. 590:128–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fabrizio DA, George TJ Jr, Dunne RF,
Frampton G, Sun J, Gowen K, Kennedy M, Greenbowe J, Schrock AB,
Hezel AF, et al: Beyond microsatellite testing: Assessment of tumor
mutational burden identifies subsets of colorectal cancer who may
respond to immune checkpoint inhibition. J Gastrointest Oncol.
9:610–617. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Santin AD, Bellone S, Buza N, Choi J,
Schwartz PE, Schlessinger J and Lifton RP: Regression of
chemotherapy-resistant polymerase ε (POLE) ultra-mutated and MSH6
hyper-mutated endometrial tumors with nivolumab. Clin Cancer Res.
22:5682–5687. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Monu NR and Frey AB: Myeloid-derived
suppressor cells and anti-tumor T cells: A complex relationship.
Immunol Investig. 41:595–613. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Samstein RM, Lee CH, Shoushtari AN,
Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ,
Omuro A, et al: Tumor mutational load predicts survival after
immunotherapy across multiple cancer types. Nat Genet. 51:202–206.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Marabelle A, Fakih MG, Lopez J, Shah M,
Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin
JA, Miller W, et al: 1192O-Association of tumor mutational burden
with outcomes in patients with select advanced solid tumors treated
with pembrolizumab in KEYNOTE-158. Ann Oncol. 30:v477–v478. 2019.
View Article : Google Scholar
|
